不同EGFR基因状态肺癌患者p53、COX-2表达及其临床意义

doi:10.3969/j.issn.1671-7171.2021.03.019

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1197 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To investigate the expression of P53 protein and cyclooxygenase-2 (COX-2) in lung cancer patients with different epidermal growth factor receptor (EGFR) gene status, and analyze their clinical value. 【Methods】The clinical data of 96 patients with lung cancer admitted to our hospital from April 2017 to April 2018 were retrospectively analyzed. All patients were confirmed by pathological puncture. The mutation of EGFR gene was detected by Taqman-ARMS method. According to the results of EGFR mutation, patients were further divided into the mutant group and the wild type group. The expression of p53 and COX-2 in lung cancer tissues was determined by immunohistochemical method. Then the expression of p53 and COX-2 in the mutant group and the wild type group was compared. The patients were followed up for 12 months. Survival and death were analyzed. The survival and death of patients with different expression of p53 and COX-2 were compared as well. The risk factors of poor prognosis of lung cancer patients were analyzed by logistic regression model. 【Results】The mutation detection showed that there were 42 (43.75%) cases of the EGFR mutation and 54 (56.25%) cases of wild type EGFR. The positive expression rates of p53 and COX-2 in the EGFR mutant group were 33.33% and 40.48% respectively, which were significantly lower than those in wild type EGFR group (57.41% and 61.11%, respectively,)( P <0.05).During the follow-up period of all 96 patients, 29 (30.21%) died and 67 (69.79%)survived. Of which, the survival rate of p53 positive patients was 53.33%, significantly lower than that of p53 negative patients (84.31%); and the mortality rate of p53 positive patients was 46.67%, which was significantly higher than that of p53 negative patients (15.69%) ( P <0.05).The survival rate of COX-2 positive patients was 56.00%, which was significantly lower than that of COX-2 negative patients (84.78%). The death rate of COX-2 positive patients was 44.00%, which was significantly higher than that of COX-2 negative patients (15.22%) ( P <0.05). Logistic regression analysis showed that the degree of differentiation (moderate to low differentiation), stage of tumors (Ⅲ-Ⅳ), lymph node metastasis, diameter of tumors (> 3cm), p53 positive and COX-2 positive expression were risk factors for poor prognosis in patients with lung cancer ( P <0.05). 【Conclusion】The positive rates of p53 and COX-2 in lung cancer patients with EGFR gene mutation were lower, and the mortality risk of p53 and COX-2 positive patients was higher. Both of them were risk factors for poor prognosis of lung cancer.

Key words： Lung Neoplasms/GE Lung Neoplasms/PA Receptor Epidermal Growth Factor Oxidoreductases

Received: 29 August 2019

PACS:

R734.2

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	BAI Guo-dong
	WANG Kai-bin

Cite this article:

BAI Guo-dong,WANG Kai-bin. Expression Characteristics and Clinical Value of p53 and COX-2 in Lung Cancer Patients with Different EGFR Gene Status[J]. JOURNAL OF CLINICAL RESEARCH, 2021, 38(3): 385-388.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2021.03.019 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2021/V38/I3/385

[1] Mckay JD, Hung RJ, Han Y, et al . Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes[J]. Nature Genetics, 2017, 49(7):1126-1132.
[2] Hellmann MD, Ciuleanu TE, Pluzanski A, et al . Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden[J]. N Engl J Med, 2018, 378(22):2093-2104.
[3] Singh M, Jadhav HR.Targeting non-small cell lung cancer with small-molecule EGFR tyrosine kinase inhibitors[J]. Drug Discov Today, 2017, 23(3):745-753.
[4] 徐燕. 肺癌组织中PCNA、p63和p53蛋白的表达及临床意义[J].现代生物医学进展, 2017, 17(10):1924-1926.
[5] 尚自强, 童莹, 宋佳,等. 肺腺癌组织中RNA结合基序蛋白38和p53基因的表达及其临床意义[J].中国肿瘤生物治疗杂志, 2017, 24(8):900-903.
[6] 王铁延, 陈修文, 汤显斌,等. COX-2和survivin蛋白在非小细胞肺癌中的表达情况及临床意义[J].癌症进展, 2018, 16(3):375-378.
[7] 王中原, 黄轶洲, 黄可, 等.环氧合酶2对肺癌细胞FOXC2的表达及侵袭能力的影响[J].江苏医药,2018, 44(12):1373-1377.
[8] 邸庆国, 张玲, 买智涛,等. 非小细胞肺癌患者中EGFR与TTF-1表达及与患者预后关系的研究[J].临床肺科杂志, 2017, 22(6):999-1003.
[9] 夏凡, 王仪民, 王辉.P53通过促进miR-145的表达抑制肺腺癌A549细胞的干细胞特性[J].中国肿瘤生物治疗杂志,2017, 24(1):58-63.
[10] 刘东芳, 王晓红, 刘春秋,等. p53蛋白在非小细胞肺癌中表达及与其临床特征、同步放化疗疗效的关系分析[J].实用癌症杂志, 2016, 31(1):26-28.
[11] Haratani K, Hayashi H, Tanaka T, et al . Tumor Immune Microenvironment and nivolumab efficacy in EGFR mutation-positive non-small cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.[J]. Ann Oncol, 2017, 28(7):1532-1539.
[12] 牛艳清, 肖鹏, 王云峰. 非小细胞肺癌组织中COX-2和血管内皮生长因子免疫反应性增强而E-钙粘素免疫反应性减弱[J].中国组织化学与细胞化学杂志, 2016, 25(4):349-354.
[13] 方志红, 李天苗, 许荣忠,等. 246例非小细胞肺癌的预后影响因素分析[J].现代肿瘤医学, 2017, 25(8):69-71.
[14] 王阳, 张黎黎, 卢颖,等. p53表达对老年晚期非小细胞肺癌化疗效果的影响研究[J].中国全科医学, 2015, 18(9):989-993.
[15] 邓汉宇, 王玺, 李刚,等. COX-2与EGFR信号通路的联合抑制在晚期非小细胞肺癌治疗中的应用[J].中国胸心血管外科临床杂志, 2016, 23(3):284-288.
[16] 张蕾, 任中海, 薛永飞.非小细胞肺癌组织中miR-219和环氧合酶-2表达水平联合预测新辅助化疗患者预后的价值分析[J].中国地方病防治杂志,2016, 31(3):300-301.